(Press-News.org) Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis. Currently there are no pharmacological or cell-based treatments for ARDS.
Dr. Zhao’s research established that a gene called FOXM1 is important in the repair of blood vessel through regeneration of endothelial cells, which line the vessels of the lung. He found that aging impairs this gene’s expression, which may be responsible for the high fatality rate from ARDS in people over 75 years of age – 10 times higher compared to young adults.
Working with a mouse model, Dr. Zhao also demonstrated that FOXM1 expression could be reactivated by two methods, which restore the gene’s function and improve survival from ARDS in the aged mice. As seen in aged mice, FOXM1 expression was inhibited in elderly COVID-19 patients. His findings were published in the journal Science Translational Medicine.
One approach involved a low dose of a repurposed FDA-approved cancer drug, decitabine, which was successful at reactivating FOXM1 expression, and so promoting vascular repair and regeneration. This drug currently is in a clinical trial for treating severe COVID-19. Dr. Zhao’s findings suggest that a lower and safer dose could be used, and that the treatment should be targeted to older patients, since the gene’s activity remains intact in younger people.
“We found that decitabine improved vascular repair, inflammation resolution and survival in aged mice, but the drug had no effects on vascular repair in young adult mice,” said Dr. Zhao, Director of the Program for Lung and Vascular Biology and Head of Section for Injury Repair and Regeneration Research at Manne Research Institute at Lurie Children’s, as well as Professor of Pediatrics, Medicine and Pharmacology at Northwestern University Feinberg School of Medicine. “It would be important to focus decitabine treatment on the elderly population, in which FOXM1 expression needs to be activated to promote recovery and reduce mortality. The next step is a clinical trial of a lower dose of the drug for ARDS in the elderly.”
Dr. Zhao also demonstrated effectiveness of an alternative approach to reactivate the gene – endothelium-targeted nanoparticle gene delivery – a technology he developed and patented. It is a more precise strategy, which may also be safer than decitabine treatment.
“Because FOXM1 is also an oncogene, unwanted induction of FOXM1 in other cell types by decitabine treatment may be a cause for concern,” he explained. “Our nanoparticle gene delivery system delivers FOXM1 only in endothelial cells, where it is needed for lung injury repair and regeneration. This strategy carries great potential for treating any disease caused by endothelial dysfunction including cancer and cancer metastasis. It will need further testing before clinical use.”
Dr. Zhao is the William G Swartchild, Jr. Distinguished Research Professor at Lurie Children’s.
Research at Ann & Robert H. Lurie Children’s Hospital of Chicago is conducted through Stanley Manne Children’s Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children’s is a nonprofit organization committed to providing access to exceptional care for every child. It is ranked as one of the nation’s top children’s hospitals by U.S. News & World Report. Lurie Children’s is the pediatric training ground for Northwestern University Feinberg School of Medicine.
Promising gene-based approaches to repair lethal lung injury in the elderly from COVID-19, pneumonia, flu, sepsis
ELSE PRESS RELEASES FROM THIS DATE:
Lifesaving addiction medications are rarely started following opioid overdose emergencies
Could future opioid overdoses, fatalities and other harms of opioid addiction be prevented if hospital emergency departments made better use of effective medications for opioid addiction? A team of University of Michigan researchers thinks so. Led by Thuy Nguyen of U-M's School of Public Health, the researchers analyzed national Medicaid claims data of patients ages 12 to 64 treated at U.S. emergency departments for opioid overdoses in 2018. They focused on ED visits for opioid overdose and the rate of initiation of FDA-approved medications for opioid addiction, including buprenorphine, methadone and extended release naltrexone. The ...
Disparities in flu vaccine uptake persist in people with kidney disease
Among adults with chronic kidney disease (CKD) enrolled in the Chronic Renal Insufficiency Cohort (CRIC), young age, Black race, and low levels of education and income were associated with lower likelihood of getting an annual flu shot. Identifying risk factors for not receiving a flu vaccine (“non-vaccination”) in people living with kidney disease, who are at risk of flu and its complications, could inform strategies for improving vaccine uptake. In this study published in the American Journal of Kidney Diseases (AJKD), researchers led by Junichi Ishigami examined whether demographic factors, social ...
A suit of armor for cancer-fighting cells
In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients’ T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer. Six CAR T cell therapies have secured FDA approval, and several more are in the pipeline. However, these therapies come with severe and potentially lethal side effects, namely cytokine release syndrome (CRS) and neurotoxicity. These drawbacks manifest as a range of symptoms—from high fever and vomiting to multiple ...
Dana-Farber leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma
EMBARGOED: September 18, 2023 4PM EST CONTACT: Nicole Oliverio, firstname.lastname@example.org, 617-257-0454 Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that ...
New research highlights importance of equity in education
A new study looks at the impact of learning environments on the academic success of racialized students. Compared to their peers, these students feel they have less control in their academic environment, less confidence and self-efficacy in their academic abilities, and weaker connections to other students and professors. The University of Ottawa study underscores that higher education institutions must recognize and address the specific needs of their racialized student communities and create inclusive learning environments that better meet these needs. Failing to do so could affect the overall psychological well-being and academic performance ...
Cell therapy can reduce risk of death from COVID-19 by 60%, study shows
The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States. Their findings are reported in an article published in the journal Frontiers in Immunology. The review covers 195 clinical trials of advanced cell therapies targeting COVID-19 that were conducted in 30 countries between January 2020 and December 2021, as well as 26 trials with outcomes published by July 2022. Cell therapy has come into increasingly frequent use in recent years ...
The pace of climate-driven extinction is accelerating, a UArizona-led study shows
Climate change is causing extinctions at an increasing rate, a new study by the University of Arizona researchers shows. They surveyed populations of the Yarrow's spiny lizard in 18 mountain ranges in southeastern Arizona and analyzed the rate of climate-related extinction over time. "The magnitude of extinction we found over the past seven years was similar to that seen in other studies that spanned almost 70 years," said John J. Wiens, a professor in the Department of Ecology and Evolutionary Biology at UArizona, ...
Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical setting
Reston, VA—A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the September issue of The Journal of Nuclear Medicine. Epithelial ovarian cancer is the most lethal ovarian cancer and frequently presents as advanced-stage disease, ...
Gene links exercise endurance, cold tolerance, and cellular maintenance in flies
EMBARGOED FOR RELEASE UNTIL September 18, 2023 at 3:00 PM U.S. Eastern time As the days get shorter and chillier in the northern hemisphere, those who choose to work out in the mornings might find it harder to get up and running. A new study in PNAS identifies a protein that, when missing, makes exercising in the cold that much harder—that is, at least in fruit flies. A team from University of Michigan Medical School and Wayne State University School of Medicine discovered the protein in flies, which they named Iditarod after the famous long distance dog sled across Alaska, while studying metabolism and the effect of stress on the body. They were particularly ...
Eureka baby! Groundbreaking study uncovers origin of ‘conscious awareness’
Living things act with purpose. But where does purpose come from? How do humans make sense of their relation to the world and realize their ability to effect change? These fundamental questions of agency – acting with purpose – have perplexed some of the greatest minds in history including Sir Isaac Newton, Charles Darwin, Erwin Schrödinger and Niels Bohr. A Florida Atlantic University study reveals groundbreaking insight into the origins of agency using an unusual and largely untapped source – human babies. Since goal-directed action appears in the first months ...